OUR SCIENCE

An investigational small-molecule approach to reversal.

Investigational product

Ciraparantag is an investigational, synthetic small molecule being developed for reversal of factor Xa inhibitor anticoagulation in patients with major bleeding when medically indicated.

Abstract visualization of molecular interactions converging on a central form

Ciraparantag (PW-977)

Illustrative rendering of a ciraparantag vial labeled investigational drug — Illustrative rendering; final packaging may differ. Ciraparantag is investigational and is not FDA-approved. Safety and efficacy have not been established.

The program’s current clinical focus is reversal of factor Xa inhibitor anticoagulation in patients with major bleeding when medically indicated.

Ciraparantag is being developed as an intravenous, ready-to-use treatment intended for urgent clinical settings where timely anticoagulant reversal may be needed.

EVIDENCE, IN CONTEXT

What has been studied.

PRECLINICAL

Reversal in bleeding models

Published animal studies reported that a single intravenous dose of ciraparantag reduced blood loss in anticoagulated external and internal bleeding models. These nonclinical findings do not establish efficacy in patients.

Ansell et al. · Blood (2021) →

CLINICAL

Studies in anticoagulated volunteers

Published randomized trials evaluated ciraparantag in healthy volunteers receiving apixaban, rivaroxaban, edoxaban, or enoxaparin and reported pharmacodynamic findings. These studies did not evaluate clinical hemostasis in patients with major bleeding.

Apixaban and rivaroxaban · European Heart Journal (2022) →Edoxaban · Thrombosis and Haemostasis (2017) →Enoxaparin · Thrombosis Research (2016) →

CLINICAL PRIORITY

Pursuing rapid reversal of factor Xa inhibitor anticoagulation in patients with major bleeding.

Pinwheel’s development strategy is directed toward clinically meaningful evidence in patients experiencing major bleeding, supported by appropriate pharmacodynamic and safety assessments.